Compare Shell PLC (SHEL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs Vertex Pharmaceuticals Incorporated — how do they compare? Shell PLC trades at $87.12 (market cap $235.24B), while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Shell PLC is the larger of the two by market cap, and Shell PLC pays a 3.63% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SHEL | VRTX | |
|---|---|---|
Market Cap | $235.24B | $121.95B |
Sector | Energy | Health |
52-Week High | $94.15 | $529.59 |
52-Week Low | $70.31 | $366.54 |
Enterprise Value | $287.77B | $116.69B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $87.20, showing modest daily decline but maintaining strong technical momentum with bullish moving averages. The stock offers attractive valuation with P/E of 13.43 and P/S of 0.94, supported by solid profitability metrics including 7.01% net margin and 10.64% ROE. Recent Q1 2026 earnings beat expectations at $2.44 EPS versus $2.14 forecast, while the company expands LNG operations in the Caribbean and advances Venezuela gas projects.
Shell presents compelling value with 30% upside to consensus price target of $114.13, supported by 69% analyst buy ratings. However, investors face risks from volatile oil prices, Middle East production disruptions, and declining cash flow trends. The current technical overbought condition suggests potential near-term consolidation before further gains.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
